Neuroproteomics

The Neuroproteomics Special Issue overviews the unique challenges that must be addressed to carry out meaningful MS/proteomics analyses on neural tissues and the technologies that are available to meet these challenges. The articles on Alzheimer's disease, addiction, and schizophrenia illustrat...

Full description

Saved in:
Bibliographic Details
Main Author: Williams, Kenneth R. (auth)
Other Authors: Nairn, Angus C. (auth)
Format: Electronic Book Chapter
Language:English
Published: MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:
n/a
DIA
PRM
PSD
PKA
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_54529
005 20210211
003 oapen
006 m o d
007 cr|mn|---annan
008 20210211s2020 xx |||||o ||| 0|eng d
020 |a books978-3-03928-107-7 
020 |a 9783039281077 
020 |a 9783039281060 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-03928-107-7  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
100 1 |a Williams, Kenneth R.  |4 auth 
700 1 |a Nairn, Angus C.  |4 auth 
245 1 0 |a Neuroproteomics 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (318 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a The Neuroproteomics Special Issue overviews the unique challenges that must be addressed to carry out meaningful MS/proteomics analyses on neural tissues and the technologies that are available to meet these challenges. The articles on Alzheimer's disease, addiction, and schizophrenia illustrate how MS/proteomics technologies can be used to improve our ability to diagnose and understand the molecular basis for neurological diseases. Several articles will be of interest to investigators beyond the field of neurological disorders. The review on the discovery of biofluid biomarkers of neurodegenerative dementias will be of interest to investigators searching for other disease biomarkers. Similarly, the review on the role of neuroproteomics in elucidating mechanisms of drug addiction provides an overview of the utility of MS/proteomics approaches for addressing critical questions in addiction neuroscience that should be applicable to investigators involved in virtually any area of biomedical research. Likewise, the article on developing targeted MS approaches for quantifying postsynaptic density proteins will be useful for any investigator who wishes to design targeted assays for virtually any protein. Finally, the peroxidase-mediated proximity labeling technology, described in the article on mapping the proteome of the synaptic cleft, will be of interest to investigators interested in mapping other spatially restricted proteomes. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by-nc-nd/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a n/a 
653 |a analgesia 
653 |a quantitative phosphoproteomics 
653 |a neurodegeneration 
653 |a neuron 
653 |a neuronal circuits 
653 |a mating 
653 |a sex-specific differences 
653 |a AMPA receptor complex 
653 |a parallel reaction monitoring 
653 |a splicing 
653 |a phosphorylation 
653 |a peptidylglycine ?-amidating monooxygenase 
653 |a pherophorin 
653 |a Alzheimer's disease 
653 |a neuroscience 
653 |a yohimbine 
653 |a synapses 
653 |a adolescence 
653 |a conformational antibody 
653 |a opioid receptors 
653 |a protein interaction networks 
653 |a Alzheimer's Disease 
653 |a transmembrane AMPA receptor regulatory protein 
653 |a neuroproteome 
653 |a ethanol 
653 |a U1 snRNP 
653 |a mass spectroscopy 
653 |a morphine 
653 |a protein phosphatase-1 
653 |a neuroproteomics 
653 |a axons 
653 |a reinstatement 
653 |a DIA 
653 |a voltage gated channels 
653 |a prohormone convertase 
653 |a postsynaptic density 
653 |a neuroimmune 
653 |a dendrites 
653 |a carboxypeptidase 
653 |a GPCR signaling 
653 |a CaMKII 
653 |a FGF14 
653 |a SynCAM 
653 |a nicotinic receptor 
653 |a synaptic plasticity 
653 |a plasma 
653 |a serum 
653 |a corticosterone 
653 |a dopamine 
653 |a Receptor-type tyrosine-protein phosphatase zeta 
653 |a Ptprz1 
653 |a PRM 
653 |a cell type 
653 |a schizophrenia 
653 |a laser capture microdissection 
653 |a synapse specificity 
653 |a LC-MS/MS 
653 |a mouse 
653 |a drug abuse 
653 |a synaptic cleft 
653 |a striatum 
653 |a Cadm 
653 |a cytokine 
653 |a spinophilin 
653 |a PSD 
653 |a trans-synaptic adhesion 
653 |a nicotine 
653 |a proximity labeling 
653 |a biomarkers 
653 |a addiction 
653 |a PKA 
653 |a synapse 
653 |a proteome 
653 |a signal peptide 
653 |a ventral tegmental area 
653 |a protein aggregation 
653 |a cerebrospinal fluid 
653 |a bioinformatics 
653 |a progressive ratio 
653 |a interactome 
653 |a subtilisin 
653 |a affinity chromatography 
653 |a basal ganglia 
653 |a cocaine 
653 |a targeted proteomics 
653 |a postsynaptic 
653 |a mass spectrometry 
653 |a connectome 
653 |a quantitative mass spectrometry 
653 |a biotinylation 
653 |a proteomics 
653 |a amphetamine 
653 |a autism 
653 |a data-independent acquisition 
653 |a excitatory/inhibitory tone 
653 |a neuropeptidomics 
653 |a matrix metalloproteinase 
653 |a cilia 
653 |a R-PTP-zeta 
653 |a cognitive impairment 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/2022  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/54529  |7 0  |z DOAB: description of the publication